Purpose
To establish whether Bezafibrate could retard or prevent the progression of coronary atherosclerosis
References
De Faire, Ericsson CG, Hamsten A, Nilsson J: Design features of a 5 year Bezafibrate Coronary Atherosclerosis
Intervention Trial (BECAIT). Drugs Exp Clin Res 1995, 21:105-124.
Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on
progression of coronary artery disease in young male postinfarction patients.
Lancet 1996, 347:849-853.
de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A: Secondary preventive potential of lipid-lowering drugs.
The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996, 17(Suppl F):37-42.
de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A: Retardation of Coronary Atherosclerosis: The
Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Other Angiographic Trials. Cardiovasc Drugs Ther
1997, 11:257-263.
Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques
causing 20% to 50% diameter narrowing. Am J Cardiol 1997, 80:1125-1129. |
Farmacêutica